Everolimus News and Research

RSS

Chinese SFDA approves Abbott's XIENCE V drug eluting stent for treating coronary artery disease

Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.

14 Sep 2009

Abbott introduces XIENCE PRIME Everolimus Eluting Coronary Stent System for global market

Abbott (NYSE: ABT) today announced at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

31 Aug 2009

Boston Scientific to discuss final results of MADIT-CRT trial at the European Society of Cardiology Congress

Boston Scientific Corporation today announced the schedule of the Company's major events and news announcements for the European Society of Cardiology (ESC) Congress, which runs from August 29 to September 2 in Barcelona. Highlights include final results from the MADIT-CRT trial and two-year results from the SYNTAX trial.

28 Aug 2009

Boston Scientific launches 3rd generation platinum chromium drug-eluting stent

Boston Scientific Corporation today announced the launch of the Platinum chromium Taxus Element Paclitaxel-Eluting Coronary Stent System in select markets worldwide. The Taxus Element Stent features a new Platinum chromium alloy engineered specifically for coronary stent applications and represents the Company's third-generation drug-eluting stent (DES) technology.

19 May 2009

Pancreatic cancer cells targeted with combo therapy

A combination of two targeted therapies packs a powerful punch to kill pancreatic cancer cells in the laboratory, Mayo Clinic cancer researchers report.

21 Apr 2009

FDA approves Afinitor oral tablets (everolimus) for advanced form of kidney cancer

The U.S. Food and Drug Administration today approved Afinitor oral tablets (everolimus) for the treatment of patients with advanced kidney cancer whose disease has progressed after treatment with other cancer therapies.

30 Mar 2009

Trial reinforces safety and efficacy of Boston Scientific's two drug-eluting stent platforms

Boston Scientific Corporation has welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials.

29 Mar 2009

Bioabsorbable stents show promise

A study published online in The Lancet presented two year data for the bioabsorbable everolimus coronary stent.

15 Mar 2009

Abbott starts trial of 2.25 mm stent system

Abbott has announced the start of SPIRIT Small Vessel, a clinical trial evaluating a 2.25 mm size of the XIENCE V Everolimus Eluting Coronary Stent System.

17 Dec 2008

FDA approves second-generation TAXUS Liberte Paclitaxel-Eluting Coronary Stent System

Boston Scientific Corporation has announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its second-generation TAXUS Liberte Paclitaxel-Eluting Coronary Stent System.

12 Oct 2008

Drug-releasing stent shows promise for improving outcomes in patients with coronary artery disease

For patients who underwent angioplasty to open narrowed coronary arteries, the use of stents releasing the drug everolimus reduced the rate of renarrowing of the arteries and significantly reduced the risk of major cardiac events, compared to the widely-used paclitaxel-releasing stents, according to a study in the April 23/30 issue of JAMA, the Journal of the American Medical Association.

22 Apr 2008

First clinical trial data of a fully bioabsorbable drug-eluting stent

Data published today in The Lancet from ABSORB, the world's first clinical trial of a fully bioabsorbable drug eluting stent for the treatment of coronary artery disease, demonstrated no stent thrombosis, no clinically driven target lesion revascularizations (re-treatment of a diseased lesion), and a low (3.3 percent) rate of major adverse cardiac events (MACE) in 30 patients out to one year.

14 Mar 2008

SPIRIT III trial shows fewer major adverse cardiac events

Late breaking results from the SPIRIT III trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that after 12 months, there were significantly fewer major adverse cardiac events (MACE) such as heart attacks, deaths from cardiac causes or repeat procedures (angioplasty or surgery) to clear the original vessel blockage after using a Xience V everolimus-eluting coronary stent than a Taxus paclitaxel-eluting stent.

24 Oct 2007

New anti-rejection medication 6-month results for heart transplant recipients to be released

New clinical trial results for heart transplant patients will be released at the upcoming International Society for Heart and Lung Transplantation (ISHLT) 27th Annual Meeting and Scientific Sessions at the Hilton San Francisco, April 25-28, 2007.

20 Apr 2007

Ultrasound targets angioplasty

World Congress of Cardiology 2006 - A simple technique - combining cardiac ultrasound with a heart muscle-stimulating drug - can identify the MI patients who would benefit most from angioplasty after thrombolysis, reports a study in Hot Line session II.

6 Sep 2006

Lack of response to herceptin may be reversed with PI3K inhibiting agents

Breast cancer patients with HER2-positive tumors who don't respond to Herceptin (trastuzumab) may benefit from cocktail therapy that includes Herceptin along with one or more PI3K inhibiting agents, say researchers at the University of Texas M. D. Anderson Cancer Center.

11 Apr 2006

New stent appears safe and effective for preventing arteries from reclosing in coronary heart disease patients

A new stent appears safe and effective for preventing arteries from reclosing in coronary heart disease patients, based on one-year results of the first human trial using this stent reported in today’s rapid access issue of Circulation: Journal of the American Heart Association.

6 May 2004